Printer Friendly
The Free Library
4,637,975 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

A Report Covering Merck KGaA, Including Their Deals, Financial Information, and Partnering Companies over a Five Year Period.


DUBLIN Dublin, city, Republic of Ireland
Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River.
, Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles.  -- Research and Markets (http://www.researchandmarkets.com/reports/c26873 ) has announced the addition of Merck KGaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article.  Deals Briefing to their offering.

Description

Merck KGaA Deals briefing provides an in-depth in-depth
adj.
Detailed; thorough: an in-depth study.


in-depth
Adjective

detailed or thorough: an in-depth analysis

 view of the 83 deals made by Merck KGaA and its subsidiaries with 116 partnering companies between 2000 and 2005, in a clear and accessible PDF (Portable Document Format) The de facto standard for document publishing from Adobe. On the Web, there are countless brochures, data sheets, white papers and technical manuals in the PDF format.  format.

Chapter 1: Company profile

An overview of the company, including contact details, a summary of business and partnering interests, and a review of management

Chapter 2: Financial data and deals overview

A summary of the company's financial status and overview of the numbers of deals by deal type, therapy focus, deal stage and industry sector.

Chapter 3: Summary of deals

A comprehensive overview listing deals by partner company, therapy focus and development stage, with a full index of all the deals announced.

Chapter 4: List of deals

A detailed listing of all the company's deals and alliances announced between January January: see month.  2000 and July July: see month.  2005.

Every deal is fully categorized cat·e·go·rize  
tr.v. cat·e·go·rized, cat·e·go·riz·ing, cat·e·go·riz·es
To put into a category or categories; classify.



cat
, includes a detailed description, and includes financials such as headline value, upfront payments and royalty rates, where disclosed.
Scope
The report contains:
a brief company profile including subsidiary names
financial information where disclosed
a deals overview
specialized indexes including deals by partner company, subsidiary
company, therapy focus and development stage
a detailed listing of the company's deals and alliances.

Key questions answered
Merck KGaA Deals briefing provides a comprehensive summary of the
deals and alliances announced by the company and its subsidiaries
between January 2000 and July 2005. This report helps in:
identifying active partners
tracking competitor activity
benchmarking deals
comparing the finances of different deal types.

Merck KGaA Deals briefing brings all relevant partnering deals into
one place, providing a reference to deal making by Merck KGaA.

Forecasts, projections, market estimates
This report provides: a financial summary table detailing the yearly
total revenues, pharma revenues, R&D spend and profit of the company;
and a series of tables detailing the number of deals made by deal
type, by therapy focus, by development stage and by industry sector.

Who should buy the report
This report is essential reading for board and executive management,
and individuals in:
business development
licensing/partnering
deal making
business strategy
marketing and promotion
distribution and manufacturing (including contract services).

Topics Covered
Introduction
About Partneringdesk Deals briefings
Chapter 1: Company profile
Chapter 2: Financial data and deals overview
Chapter 3: Summary of deals
Deals involving Merck KGaA by partner company
Deals involving Merck KGaA by subsidiary
Deals involving Merck KGaA by therapy focus
Deals involving Merck KGaA by development stage
Chapter 4: List of deals
Glossary
List of Tables
Table 2.1 Merck KGaA financial summary
Table 2.2 Merck KGaA deals by deal type
Table 2.3 Merck KGaA deals by therapy focus
Table 2.4 Merck KGaA deals by development stage
Table 2.5 Merck KGaA deals by industry sector


Companies Mentioned

Biovation Limited, EMD EMD Electromechanical dissociation, see there  Biosciences, EMD Chemicals, EMD Pharmaceuticals, Genpharm

Lipha, Merck Eprova AG, Merck Eurolab (until 2004-02-01), Merck Generics Group, Merck Medication Familiale, Merck NM, Merck Pharma SpA, Molteni Pharma SpA, NM Pharma, ProteoPlex, VWR International VWR International is a global leader in the distribution of research laboratory products, with over 1,200,000 items to more than 250,000 customers in North America and Europe. The U.S. division is headquartered in West Chester, Pennsylvania.  (until 2004-02-01)

For more information visit http://www.researchandmarkets.com/reports/c26873
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Company Profile
Date:Nov 11, 2005
Words:532
Previous Article:Evergreen Solar to Present at Pacific Growth Equities Top Picks in Tech Conference; Company to Webcast Presentation Live at 9:30 a.m. ET on November...
Next Article:The lAtest Edition Examines Alternative Fuel and Car Development in the Automotive World, as They Attempt to Try to Improve the Quality of Air.
Topics:



Related Articles
An in-Dept Evaluation of Merck & Co Inc Deals Covering Deals Made with 162 Partnering Companies.
Learn How Product Teams Allocate Resources to Overcome Challenges from the Pre-Clinical Period to Post-Launch - Blockbuster Brand Resource Allocation.
Examine Brand Spending by Time Period (Phase III, Registration and Launch, and First 12-18 Months on Pharmaceutical Market).
The Merck & Co Inc Product Pipeline Report Delivers the Latest and the Most Comprehensive Intelligence Available on Merck & Co Inc's Current Pipeline...
$100 Billion of US and European Pharmaceutical Company Revenues Threatened by Generic Drugs Forecasts URCH Publishing.
SLOAN CANCER VACCINE PHASE III STUDY BEGINS.
The Germany Pharmaceuticals & Healthcare Report Provides Independent Forecasts And Competitive Intelligence On Germanys Pharmaceuticals & Healthcare...
The Swiss Pharmaceutical Market Is Projected to Be Worth US$7bn by 2010.
Research and Markets: 2007 - Forest Laboratories Successfully Complete the Acquisition of Cerexa.
Research and Markets: Merck Generics Had Sales of Just Under 1.8 Billion Euros in 2005.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles